{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:44:37Z","timestamp":1769877877580,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T00:00:00Z","timestamp":1497830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic kidney disease (<jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>) patients have a high burden of cardiovascular disease. In the general population, lipid metabolism disorders, which cause the initiation and progression of atherosclerotic vascular changes, are major targets for preventive and therapeutic strategies in cardiovascular medicine. However, data from large cohort studies and from clinical trials suggest that the treatment guidelines on cardiovascular disease prevention and therapy cannot uncritically be transferred from individuals with intact renal function to <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> patients. Thus, unlike in the general population, neither plasma levels of <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\u2010cholesterol, nor the key parameter of <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\u2010cholesterol function\u2014that is, cholesterol efflux capacity\u2014predicts future cardiovascular events. Therefore, <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\u2010cholesterol should presently not be considered as therapeutic target in <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> patients. In contrast, lowering of <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010cholesterol has been shown to reduce cardiovascular events at least among nondialysis <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> patients. The cardiovascular benefit of targeting <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010cholesterol among dialysis <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> patients is less evident. We strongly believe that at least some subgroups of dialysis patients may profit from such treatment, particularly those with highest baseline <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\u2010cholesterol. Finally, as <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> patients have been characterized to have rather high intestinal cholesterol absorption, and relatively low hepatic cholesterol synthesis, substituting combined statin\/ezetimibe treatment for statin monotherapy may be of particular benefit for nephrologic patients.<\/jats:p>","DOI":"10.1111\/sdi.12621","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T13:52:35Z","timestamp":1497880355000},"page":"390-394","source":"Crossref","is-referenced-by-count":12,"title":["Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients"],"prefix":"10.1111","volume":"30","author":[{"given":"Gunnar H.","family":"Heine","sequence":"first","affiliation":[{"name":"Saarland University Medical Center Homburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyrill S.","family":"Rogacev","sequence":"additional","affiliation":[{"name":"University Heart Center Luebeck Medical Clinic II (Cardiology\/Angiology\/Intensive Care Medicine) University Hospital Schleswig\u2010Holstein Luebeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Weing\u00e4rtner","sequence":"additional","affiliation":[{"name":"Department of Cardiology University Hospital Oldenburg European Medical School Oldenburg\u2010Groningen Carl von Ossietzky Universit\u00e4t Oldenburg Oldenburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunther","family":"Marsche","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology Medical University of Graz Graz Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61009-6"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61177-6"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61217-4"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000230"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30156-5"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001689"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.10.111"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409065"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00126-6"},{"key":"e_1_2_4_11_1","first-page":"1870","article-title":"HDL cholesterol efflux capacity and cardiovascular events","volume":"372","author":"Ritsch A","year":"2015","journal-title":"N Engl J Med"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.301373"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00730116"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013050482"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu022"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2014.07.003"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.001"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.02.009"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010111144"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011070668"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014030309"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.013"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013111212"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016030262"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.054"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014090857"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39472.580984.AE"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.31"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043545"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.12.033"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810177"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.01.003"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn580"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-1302"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.20594"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.551"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05170511"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7138.1127"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09121010"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30156-5"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsdi.12621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sdi.12621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T12:18:48Z","timestamp":1696162728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sdi.12621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/sdi.12621"],"URL":"https:\/\/doi.org\/10.1111\/sdi.12621","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,19]]}}}